Trials / Terminated
TerminatedNCT00461344
Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer
A Multicenter, Open Label, Phase II Trial Evaluating Docetaxel + Anthracycline x 4 Cycles Followed by Docetaxel Single Agent x 4 Cycles as First-Line Therapy in Patients With Her2 Negative Locally Advanced or Metastatic Breast Cancer Who Have Relapsed ≥ 12 Months From Completion of Neoadjuvant/Adjuvant Taxotere®- Based Chemotherapy
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Primary: To determine the pathological remission following the chemotherapy combination docetaxel and doxorubicin in large breast cancer Secondary: * Clinical response rate * To investigate the safety of docetaxel doxorubicin combination in the treatment for neoadjuvant chemotherapy of breast cancer * Type of surgery (radical/conservative)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Docetaxel | |
| DRUG | Doxorubicin |
Timeline
- Start date
- 2004-07-01
- Primary completion
- 2005-06-01
- Completion
- 2007-08-01
- First posted
- 2007-04-18
- Last updated
- 2008-04-03
Source: ClinicalTrials.gov record NCT00461344. Inclusion in this directory is not an endorsement.